Home Technology Radius Health is One of Farallon Capital’s Best 2014 Bets

Radius Health is One of Farallon Capital’s Best 2014 Bets

When you purchase through our sponsored links, we may earn a commission. By using this website you agree to our T&Cs.

Radius Health Inc. (NASDAQ:RDUS), MacroGenics Inc. (NASDAQ:MGNX) and Caesars Entertainment Corp. (NASDAQ:CZR) started the week off strong, making notable gains on the market this Monday. Altisource Portfolio Solutions (NASDAQ:ASPS), Gilead Sciences Inc. (NASDAQ:GILD) and EXCO Resources Inc. (NYSE:XCO), on the other hand, are taking tumbles.

Sign up for our free daily newsletter

Radius Health Surges

Radius Health Inc. climbed +16.59% today after announcing positive results from one of its drug candidates. The company has been one of Farallon Capital’s best bets of the year. The hedge fund initiated a stake in the firm during the second quarter of the year and as of the third quarter still holds 950,000 RDUS shares. The stock has climbed more than +350% in 2014.

[drizzle]

MacroGenics Inc. rallied +11.41% this Monday after inking a deal with Johnson & Johnson that could potentially be worth $700 million. The biotech company, a two-quarter George Soros holding, has gained +88.66% over the past three months.

Caesars Entertainment ended the day with an +11.19% gain on the heels of news that it will acquire Caesars Acquisition Company, one of its publicly traded subsidiaries. Leon Cooperman, John Paulson and George Soros have positions in the casino giant, which is down -30.36% year-to-date.

Altisource Portfolio Solutions Plummets Following Chairman’s Exit

Altisource Portfolio Solutions tumbled -33.47% this Monday after announcing that its Chairman of the Board is stepping down. The marketplace and transactions services provider is one of Leon Cooperman’s internationally-headquartered investments. Its price has tumbled -80% this year.

Gilead Sciences slid -14.34% today in the wake of reports that Express Scripts will cover only AbbVie’s newly-approved hepatitis C regimen – not those made by Gilead or Johnson & Johnson. Julian Robertson holds 440,000 GILD shares as of Q3 and is likely taking a hit here, given that the biopharmaceutical company has a 12% allocation in his public equity portfolio.

Long-time Wilbur Ross pick EXCO Resources dipped -11.19%. Just last week, the oil and gas company said it plans to suspend cash dividends. The stock has fallen -38.62% in the past month alone.

Sign up for our free daily newsletter

[/drizzle]

Our Editorial Standards

At ValueWalk, we’re committed to providing accurate, research-backed information. Our editors go above and beyond to ensure our content is trustworthy and transparent.

iBillionaire
Editor

Want Financial Guidance Sent Straight to You?

  • Pop your email in the box, and you'll receive bi-weekly emails from ValueWalk.
  • We never send spam — only the latest financial news and guides to help you take charge of your financial future.